Oxidative Stress Parameters, Trace Element and Quality of Life in Women Before and After Covid-19 Vaccines
Comparison of Oxidative Stress Parameters, Trace, Element and Quality of Life Levels in Healthy Women Before and After Covid-19 Vaccines
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Coronavirus disease 2019 (COVID-19) pandemic, also known as Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), caused by a coronavirus strain that is a member of the Betacoronavirus genus, affecting billions of people worldwide, has become a global health problem. Since vaccination is the most effective approach to control the COVID-19 pandemic, trials of many different vaccines have been started.
According to the data of the World Health Organization, there are 236 vaccines in total, with clinical (63) and pre-clinical (173) studies developed using 10 different methods.Types of vaccines for COVID-19 include conventionally live attenuated viruses, inactivated virus protein or polysaccharide conjugated subunit vaccines, virus-like particles (VLPs), nucleic acid (DNA and RNA), viral vectors (replicating and non-replicating), and the other vaccines composed of eccombinant proteins.
CoronaVac vaccine (inactivated + aluminum adjuvant vaccine) is a vaccine developed by the biopharmaceutical company named Sinovac Biotech Ltd. based in China, using the classical vaccine production method (inactive method). After the completion of Phase 1 and Phase 2 trials of the vaccine, Phase 3 trials were initiated in Turkey. Emergency use approval has been given for the CoronaVac vaccine by Turkish Pharmaceuticals and Medical Devices Agency after the end of these trials.Although the pathogenesis of COVID-19 is not fully understood, its clinical presentation may become heterogeneous, ranging from asymptomatic to severe disease.
It has been reported that a systemic hyperinflammatory response and associated thromboembolic complications are observed in cases with severe symptoms. In addition, it has been observed that the severity of the disease and mortality rates are lower in women compared to men in the clinical results of COVID-19.
The roles of vitamins A, B, C, D, E and folate and trace elements such as iron, zinc, magnesium, selenium and copper in supporting the immune system have been shown to have positive effects on COVID-19 disease.
Intermediates in enzymatic reactions occurring during cell metabolism (reactive oxygen species and reactive nitrogen) sometimes leak from the active site of enzymes and accidentally interact with molecular oxygen and form free oxygen radicals. Oxidative stress caused by free oxygen radicals forms the molecular basis in the development of cancer, neurodegenerative and cardiovascular diseases, diabetes and autoimmune disorders.
Social isolation rules and quarantine measures have negatively affected the daily lives of individuals physically and psychologically. In particular, the increase in the time spent at home causes individuals to have a sedentary life and cause their physical levels to decrease. This situation caused individuals to be psychologically affected by concerns about health, news watched, and the increasing number of cases day by day.
Studies have also reported negative psychological effects such as post-traumatic stress symptoms, confusion, disappointment, feeling of isolation and anger as a result of quarantine. These psychological and physical effects caused by the COVID-19 pandemic caused a decrease in the quality of life of individuals. During the COVID-19 pandemic, it has been reported that the depression and anxiety levels of healthcare workers increased and their quality of life decreased.
The aim of this study is to compare and determined and the changes of oxidative stress parameters, trace element and quality of life levels in healthy women just before the first dose of COVID-19 vaccine and on the 7th day after the second dose of COVID19 vaccine.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
İzmir, Turkey, 06580
- Kadirhan Ozdemir
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Agree to voluntarily participate in the study
Exclusion Criteria:
- Have been taking trace element supplements for the past 2 weeks
- Being pregnant
- Body mass index over 40 kg/m2
- Diagnosed with Covid-19 in advance
- Not diagnosed with any chronic disease
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Screening
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: CoronoVac Vaccine Group
|
CoronaVac vaccines will be inoculated in 2 doses with an interval of 24 days.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change of the levels of Oxidative Stress Parameter 1
Time Frame: Immediately before the first dose and 7 days after the second dose of CoronaVac vaccine
|
Oxidative Stress Parameter including Superoxide Dismutase (SOD) will be studied by photometric method in Medical Biochemistry Laboratory.
|
Immediately before the first dose and 7 days after the second dose of CoronaVac vaccine
|
|
Change of the levels of Oxidative Stress Parameter 2
Time Frame: Immediately before the first dose and 7 days after the second dose of CoronaVac vaccine
|
Oxidative Stress Parameters including Malondialdehyde (MDA) will be studied by photometric method in Medical Biochemistry Laboratory.
|
Immediately before the first dose and 7 days after the second dose of CoronaVac vaccine
|
|
Change of the levels of Oxidative Stress Parameter 3
Time Frame: Immediately before the first dose and 7 days after the second dose of CoronaVac vaccine
|
Oxidative Stress Parameter including Total Antioxidant Level (TAL) will be studied by photometric method in Medical Biochemistry Laboratory.
|
Immediately before the first dose and 7 days after the second dose of CoronaVac vaccine
|
|
Change of the levels of Oxidative Stress Parameter 4
Time Frame: Immediately before the first dose and 7 days after the second dose of CoronaVac vaccine
|
Oxidative Stress Parameters including Total Oxidant Level (TOL) will be studied by photometric method in Medical Biochemistry Laboratory.
|
Immediately before the first dose and 7 days after the second dose of CoronaVac vaccine
|
|
Change of the levels serum trace element 1
Time Frame: Immediately before the first dose and 7 days after the second dose of CoronaVac vaccine
|
Serum trace element including zinc levels will be determined by venous blood samples taken from the participants.
Serum trace element levels samples will be analyzed using the atomic absorption spectrophotometry (AAS) method.
|
Immediately before the first dose and 7 days after the second dose of CoronaVac vaccine
|
|
Change of the levels serum trace element 2
Time Frame: Immediately before the first dose and 7 days after the second dose of CoronaVac vaccine
|
Serum trace elements including selenium levels will be determined by venous blood samples taken from the participants.
Serum trace element levels samples will be analyzed using the atomic absorption spectrophotometry (AAS) method.
|
Immediately before the first dose and 7 days after the second dose of CoronaVac vaccine
|
|
Change of the levels serum trace element 3
Time Frame: Immediately before the first dose and 7 days after the second dose of CoronaVac vaccine
|
Serum trace element including potassium levels will be determined by venous blood samples taken from the participants.
Serum trace element levels samples will be analyzed using the atomic absorption spectrophotometry (AAS) method.
|
Immediately before the first dose and 7 days after the second dose of CoronaVac vaccine
|
|
Change of the levels serum trace element 4
Time Frame: Immediately before the first dose and 7 days after the second dose of CoronaVac vaccine
|
Serum trace element including sodium levels will be determined by venous blood samples taken from the participants.
Serum trace element levels samples will be analyzed using the atomic absorption spectrophotometry (AAS) method.
|
Immediately before the first dose and 7 days after the second dose of CoronaVac vaccine
|
|
Change of the levels serum trace element 5
Time Frame: Immediately before the first dose and 7 days after the second dose of CoronaVac vaccine
|
Serum trace elements including calcium levels will be determined by venous blood samples taken from the participants.
Serum trace element levels samples will be analyzed using the atomic absorption spectrophotometry (AAS) method.
|
Immediately before the first dose and 7 days after the second dose of CoronaVac vaccine
|
|
Change of the levels serum trace element 6
Time Frame: Immediately before the first dose and 7 days after the second dose of CoronaVac vaccine
|
Serum trace element including magnesium levels will be determined by venous blood samples taken from the participants.
Serum trace element levels samples will be analyzed using the atomic absorption spectrophotometry (AAS) method.
|
Immediately before the first dose and 7 days after the second dose of CoronaVac vaccine
|
|
Change of the levels serum trace element 7
Time Frame: Immediately before the first dose and 7 days after the second dose of CoronaVac vaccine
|
Serum trace element including copper levels will be determined by venous blood samples taken from the participants.
Serum trace element levels samples will be analyzed using the atomic absorption spectrophotometry (AAS) method.
|
Immediately before the first dose and 7 days after the second dose of CoronaVac vaccine
|
|
Change of the levels of quality of life
Time Frame: Immediately before the first dose and 4 weeks later
|
SF-36 Quality of Life Scale will be used to determine the quality of life level.
The scale that patients can apply themselves and in a short time; It consists of 36 items and 8 subsections.
These sections are physical functionality, social functionality, role restrictions due to physical problems, role restrictions due to emotional problems, pain, energy level / vitality / vitality, mental health, and general health perception (40).
The last 4 weeks are considered in the evaluation of the scale.
The scale gives a separate total score for each subsection.
The points obtained from the subsections are not added up.
Subdivisions rate health from 0 to 100.
While it expresses bad health status as "0 points", it refers to good health status as "100 points".
|
Immediately before the first dose and 4 weeks later
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2021-01-173
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.